Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX releases new information brochure

May 4, 2018

IR

Today 2cureX has released a new information brochure. The brochure is available for download here.

2cureX – teaser-May 2018 (.PDF)

Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX.

For more information about 2cureX:

Ole Thastrup, CEO

E-mail: ot@2cureX.com

Phone: +45 22 11 53 99

URL: www.2curex.com 

About 2cureX

2cureX has developed IndiTreat® (Individual Treatment Design) – a patented method for selecting the right drug for the right patient, thereby improving cancer treatment. Initially, IndiTreat® is targeted towards colorectal cancer; but the method is applicable to additional cancer indications (e.g. ovarian, breast and kidney cancer). The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).